Cannabinoids: A new hope for breast cancer therapy?

Cancer Treatment Reviews

Volumn 38, Issue 7, 2012, Pages 911-918

  Caffarel, María M ^a,b   Andradas, Clara ^a   Pérez Gómez, Eduardo ^a   Guzmán, Manuel ^a   Sánchez, Cristina ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Cannabinoids; G protein coupled receptors; Preclinical studies

Indexed keywords

1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; ANANDAMIDE; BEVACIZUMAB; CANNABIDIOL; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CHEMOKINE RECEPTOR CXCR4; DRONABINOL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; GEMCITABINE; LAPATINIB; NABILONE; NABIXIMOLS; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PACLITAXEL; PROGESTERONE RECEPTOR; REACTIVE OXYGEN METABOLITE; TAMOXIFEN; TEMOZOLOMIDE; TRASTUZUMAB;

APOPTOSIS; BREAST CANCER; CANCER GROWTH; CANCER PAIN; CANCER PATIENT; CELL CYCLE ARREST; CELL MIGRATION; CELL PROLIFERATION; CELL STRAIN MCF 7; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; DRUG MEGADOSE; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; GENE EXPRESSION; GLIOMA; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LUNG METASTASIS; MANTLE CELL LYMPHOMA; METASTASIS; NEUROPATHIC PAIN; NONHUMAN; PANCREAS CANCER; REVIEW; RHABDOMYOSARCOMA; SPASTICITY; TRIPLE NEGATIVE BREAST CANCER;

ANIMALS; BREAST NEOPLASMS; CANNABINOIDS; FEMALE; HUMANS; MICE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84865417165     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2012.06.005     Document Type: Review

References (75)

1. Gaoni Y., Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc 1964, 86:1646-1647.
2. Pacher P., Batkai S., Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 2006, 58:389-462.
3. Matsuda L.A., Lolait S.J., Brownstein M.J., et al. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990, 346:561-564.
4. Devane W.A., Hanus L., Breuer A., et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992, 258:1946-1949.
5. Mechoulam R., Ben-Shabat S., Hanus L., et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995, 50:83-90.
6. Sugiura T., Kondo S., Sukagawa A., et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 1995, 215:89-97.
7. Munro S., Thomas K.L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993, 365:61-65.
8. Pertwee R.G., Howlett A.C., Abood M.E., et al. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB and CB. Pharmacol Rev 2010, 62:588-631.
9. Machado Rocha F.C., Stefano S.C., De Cassia Haiek R., et al. Therapeutic use of Cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis. Eur J Cancer Care (Engl) 2008, 17:431-443.
10. Velasco G., Sánchez C., Guzmán M. Towards the use of cannabinoids as antitumour agents. Nat Rev Cancer 2012.
11. DeSantis C., Siegel R., Bandi P., et al. Breast cancer statistics, 2011. CA Cancer J Clin 2011, 61:409-418.
12. Foulkes W.D., Smith I.E., Reis-Filho J.S. Triple-negative breast cancer. N Engl J Med 2010, 363:1938-1948.
13. Higgins M.J., Baselga J. Targeted therapies for breast cancer. J Clin Invest 2011, 121:3797-3803.
14. Nilsson S., Koehler K.F., Gustafsson J.A. Development of subtype-selective oestrogen receptor-based therapeutics. Nat Rev Drug Discov 2011, 10:778-792.
15. De Petrocellis L., Melck D., Palmisano A., et al. The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proc Natl Acad Sci U S A 1998, 95:8375-8380.
16. Melck D., Rueda D., Galve-Roperh I., et al. Involvement of the cAMP/protein kinase A pathway and of mitogen-activated protein kinase in the anti-proliferative effects of anandamide in human breast cancer cells. FEBS Lett 1999, 463:235-240.
17. Melck D., De Petrocellis L., Orlando P., et al. Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation. Endocrinology 2000, 141:118-126.
18. Caffarel M.M., Moreno-Bueno G., Cerutti C., et al. JunD is involved in the antiproliferative effect of Delta(9)-tetrahydrocannabinol on human breast cancer cells. Oncogene 2008, 27:5033-5044.
19. Caffarel M.M., Sarrio D., Palacios J., et al. Delta9-tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation. Cancer Res 2006, 66:6615-6621.
20. Nasser M.W., Qamri Z., Deol Y.S., et al. Crosstalk between chemokine receptor CXCR4 and cannabinoid receptor CB2 in modulating breast cancer growth and invasion. PLoS One 2011, 6:e23901.
21. Zlotnik A., Burkhardt A.M., Homey B. Homeostatic chemokine receptors and organ-specific metastasis. Nat Rev Immunol 2011, 11:597-606.
22. Zhang H., Berezov A., Wang Q., et al. ErbB receptors: from oncogenes to targeted cancer therapies. J Clin Invest 2007, 117:2051-2058.
23. Caffarel M.M., Andradas C., Mira E., et al. Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition. Mol Cancer 2010, 9:196.
24. Ursini-Siegel J., Schade B., Cardiff R.D., et al. Insights from transgenic mouse models of ERBB2-induced breast cancer. Nat Rev Cancer 2007, 7:389-397.
25. Pertwee R.G. Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol 2009, 156:397-411.
26. Laezza C., Pisanti S., Crescenzi E., et al. Anandamide inhibits Cdk2 and activates Chk1 leading to cell cycle arrest in human breast cancer cells. FEBS Lett 2006, 580:6076-6082.
27. Ligresti A., Moriello A.S., Starowicz K., et al. Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J Pharmacol Exp Ther 2006, 318:1375-1387.
28. McAllister S.D., Christian R.T., Horowitz M.P., et al. Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells. Mol Cancer Ther 2007, 6:2921-2927.
29. McAllister S.D., Murase R., Christian R.T., et al. Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis. Breast Cancer Res Treat 2011.
30. Qamri Z., Preet A., Nasser M.W., et al. Synthetic cannabinoid receptor agonists inhibit tumor growth and metastasis of breast cancer. Mol Cancer Ther 2009, 8:3117-3129.
31. Shrivastava A., Kuzontkoski P.M., Groopman J.E., et al. Cannabidiol induces programmed cell death in breast cancer cells by coordinating the cross-talk between apoptosis and autophagy. Mol Cancer Ther 2011, 10:1161-1172.
32. Grimaldi C., Pisanti S., Laezza C., et al. Anandamide inhibits adhesion and migration of breast cancer cells. Exp Cell Res 2006, 312:363-373.
33. Laezza C., Pisanti S., Malfitano A.M., et al. The anandamide analog, Met-F-AEA, controls human breast cancer cell migration via the RHOA/RHO kinase signaling pathway. Endocr Relat Cancer 2008, 15:965-974.
34. Hoellen F., Kelling K., Dittmer C., et al. Impact of cyclooxygenase-2 in breast cancer. Anticancer Res 2011, 31:4359-4367.
35. Jaffe A.B., Hall A. Rho GTPases: biochemistry and biology. Annu Rev Cell Dev Biol 2005, 21:247-269.
36. Narumiya S., Tanji M., Ishizaki T. Rho signaling, ROCK and mDia1, in transformation, metastasis and invasion. Cancer Metastasis Rev 2009, 28:65-76.
37. Hall A. The cytoskeleton and cancer. Cancer Metastasis Rev 2009, 28:5-14.
38. Izzo A.A., Borrelli F., Capasso R., et al. Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci 2009, 30:515-527.
39. Massi P., Solinas M., Cinquina V., et al. Cannabidiol as potential anticancer drug. Br J Clin Pharmacol 2012.
40. Bisogno T., Hanus L., De Petrocellis L., et al. Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 2001, 134:845-852.
41. Salazar M., Carracedo A., Salanueva I.J., et al. Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells. J Clin Invest 2009.
42. Carracedo A., Gironella M., Lorente M., et al. Cannabinoids induce apoptosis of pancreatic tumor cells via endoplasmic reticulum stress-related genes. Cancer Res 2006, 66:6748-6755.
43. Vara D., Salazar M., Olea-Herrero N., et al. Anti-tumoral action of cannabinoids on hepatocellular carcinoma: role of AMPK-dependent activation of autophagy. Cell Death Differ 2011, 18:1099-1111.
44. Oesch S., Walter D., Wachtel M., et al. Cannabinoid receptor 1 is a potential drug target for treatment of translocation-positive rhabdomyosarcoma. Mol Cancer Ther 2009, 8:1838-1845.
45. Gustafsson K., Christensson B., Sander B., et al. Cannabinoid receptor-mediated apoptosis induced by R(+)-methanandamide and Win, 55,212-2 is associated with ceramide accumulation and p38 activation in mantle cell lymphoma. Mol Pharmacol 2006, 70:1612-1620.
46. Massi P., Vaccani A., Bianchessi S., et al. The non-psychoactive cannabidiol triggers caspase activation and oxidative stress in human glioma cells. Cell Mol Life Sci 2006, 63:2057-2066.
47. McKallip R.J., Jia W., Schlomer J., et al. Cannabidiol-induced apoptosis in human leukemia cells: a novel role of cannabidiol in the regulation of p22phox and Nox4 expression. Mol Pharmacol 2006, 70:897-908.
48. McKallip R.J., Nagarkatti M., Nagarkatti P.S. Delta-9-tetrahydrocannabinol enhances breast cancer growth and metastasis by suppression of the antitumor immune response. J Immunol 2005, 174:3281-3289.
49. Zhu L.X., Sharma S., Stolina M., et al. Delta-9-tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway. J Immunol 2000, 165:373-380.
50. Gardner B., Zhu L.X., Sharma S., et al. Methanandamide increases COX-2 expression and tumor growth in murine lung cancer. FASEB J 2003, 17:2157-2159.
51. Blazquez C., Carracedo A., Barrado L., et al. Cannabinoid receptors as novel targets for the treatment of melanoma. FASEB J 2006, 20:2633-2635.
52. Chan P.C., Sills R.C., Braun A.G., et al. Toxicity and carcinogenicity of delta 9-tetrahydrocannabinol in Fischer rats and B6C3F1 mice. Fundam Appl Toxicol 1996, 30:109-117.
53. Takeda S., Yamamoto I., Watanabe K. Modulation of Delta9-tetrahydrocannabinol-induced MCF-7 breast cancer cell growth by cyclooxygenase and aromatase. Toxicology 2009, 259:25-32.
54. Takeda S., Yamaori S., Motoya E., et al. Delta(9)-Tetrahydrocannabinol enhances MCF-7 cell proliferation via cannabinoid receptor-independent signaling. Toxicology 2008, 245:141-146.
55. Sulcova E., Mechoulam R., Fride E. Biphasic effects of anandamide. Pharmacol Biochem Behav 1998, 59:347-352.
56. Calatozzolo C., Salmaggi A., Pollo B., et al. Expression of cannabinoid receptors and neurotrophins in human gliomas. Neurol Sci 2007, 28:304-310.
57. Ellert-Miklaszewska A., Grajkowska W., Gabrusiewicz K., et al. Distinctive pattern of cannabinoid receptor type II (CB2) expression in adult and pediatric brain tumors. Brain Res 2007, 1137:161-169.
58. Sanchez C., de Ceballos M.L., Gomez del Pulgar T., et al. Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor. Cancer Res 2001, 61:5784-5789.
59. Fowler C.J., Hammarsten P., Bergh A. Tumour Cannabinoid CB(1) receptor and phosphorylated epidermal growth factor receptor expression are additive prognostic markers for prostate cancer. PLoS One 2010, 5:e15205.
60. Gustafsson S.B., Palmqvist R., Henriksson M.L., et al. High tumour cannabinoid CB1 receptor immunoreactivity negatively impacts disease-specific survival in stage II microsatellite stable colorectal cancer. PLoS One 2011, 6:e23003.
61. Zheng D., Bode A.M., Zhao Q., et al. The cannabinoid receptors are required for ultraviolet-induced inflammation and skin cancer development. Cancer Res 2008, 68:3992-3998.
62. Wang D., Wang H., Ning W., et al. Loss of cannabinoid receptor 1 accelerates intestinal tumor growth. Cancer Res 2008, 68:6468-6476.
63. Carracedo A., Lorente M., Egia A., et al. The stress-regulated protein p8 mediates cannabinoid-induced apoptosis of tumor cells. Cancer Cell 2006, 9:301-312.
64. Galve-Roperh I., Sanchez C., Cortes M.L., et al. Anti-tumoral action of cannabinoids: involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat Med 2000, 6:313-319.
65. Casanova M.L., Blazquez C., Martinez-Palacio J., et al. Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J Clin Invest 2003, 111:43-50.
66. Grotenhermen F. The toxicology of cannabis and cannabis prohibition. Chem Biodivers 2007, 4:1744-1769.
67. Portenoy R.K., Ganae-Motan E.D., Allende S., et al. Nabiximols for opioid-treated cancer patients with poorly-controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. J Pain 2012.
68. Wade D.T., Collin C., Stott C., et al. Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis. Mult Scler 2010, 16:707-714.
69. Guzman M. Cannabinoids: potential anticancer agents. Nat Rev Cancer 2003, 3:745-755.
70. Robson P. Abuse potential and psychoactive effects of delta-9-tetrahydrocannabinol and cannabidiol oromucosal spray (Sativex), a new cannabinoid medicine. Expert Opin Drug Saf 2011, 10:675-685.
71. Torres S., Lorente M., Rodriguez-Fornes F., et al. A combined preclinical therapy of cannabinoids and temozolomide against glioma. Mol Cancer Ther 2011, 10:90-103.
72. Donadelli M., Dando I., Zaniboni T., et al. Gemcitabine/cannabinoid combination triggers autophagy in pancreatic cancer cells through a ROS-mediated mechanism. Cell Death Dis 2011, 2:e152.
73. Miyato H., Kitayama J., Yamashita H., et al. Pharmacological synergism between cannabinoids and paclitaxel in gastric cancer cell lines. J Surg Res 2009, 155:40-47.
74. Gustafsson S.B., Lindgren T., Jonsson M., et al. Cannabinoid receptor-independent cytotoxic effects of cannabinoids in human colorectal carcinoma cells: synergism with 5-fluorouracil. Cancer Chemother Pharmacol 2009, 63:691-701.
75. Marcu J.P., Christian R.T., Lau D., et al. Cannabidiol enhances the inhibitory effects of delta9-tetrahydrocannabinol on human glioblastoma cell proliferation and survival. Mol Cancer Ther 2010, 9:180-189.